Chronotropic incompetence, beta-blockers, and functional capacity in advanced congestive heart failure: time to pace?

Ulrich P Jorde1, Timothy J Vittorio, Michael E Kasper

  • 1Division of Cardiology, New York Presbyterian Hospital, Columbia University College of Physicians and Surgeons, United States. upj1@columbia.edu

Insights

Chronotropic incompetence (CI) affects nearly half of heart failure patients, independent of beta-blocker use. This condition is linked to reduced exercise capacity and impaired beta-receptor sensitivity.

Area of Science:

  • Cardiology
  • Exercise Physiology

Background:

  • Chronotropic incompetence (CI) is a common finding in patients with chronic heart failure (CHF).
  • The prevalence, underlying mechanisms, and clinical associations of CI, particularly concerning beta-blocker therapy and exercise capacity, remain incompletely understood.

Purpose of the Study:

  • To investigate the prevalence of CI in systolic CHF patients.
  • To explore the relationship between CI, exercise capacity, beta-blocker use, and neurohormonal responses during exercise.

Main Methods:

  • Analysis of cardiopulmonary exercise tolerance testing data from 278 consecutive systolic CHF patients.
  • Measurement of heart rate and norepinephrine (NE) levels during exercise in a separate cohort of 24 CHF patients.

Main Results:

  • CI was present in 46% of patients and was most prevalent in those with the lowest exercise capacity (VO2 <14.0 ml/kg/min).
  • Patients with CI exhibited lower peak heart rate and VO2 but similar beta-blocker use compared to those without CI.
  • Subjects with CI showed a trend toward impaired exercise-induced NE release and significantly lower Chronotropic Responsiveness Index (CRI), indicating reduced beta-receptor sensitivity.

Conclusions:

  • CI is highly prevalent in advanced systolic CHF, affecting over 70% of patients with severe impairment, irrespective of beta-blocker use.
  • CI is associated with reduced exercise capacity and potentially impaired norepinephrine release and post-synaptic beta-receptor desensitization.
Abstract

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antiarrhythmic Drugs: Class II Agents as &#946;-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Decreased pulse rate01:14

Decreased pulse rate

Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with bradycardia...